Univercells SA (‘Univercells’) and Global Health Investment Fund (‘GHIF’) are pleased to announce the closing of a €16 million ($18.8 million) Series B equity financing. Investment proceeds will support the continued development of Univercells’ game-changing biomanufacturing technology, which has the potential to dramatically reduce the capital expenditure, physical footprint and operating costs required to produce a variety of complex biologics. The financing, which was heavily over-subscribed, is anchored by institutional commitments from prominent investment funds on three continents. In addition to GHIF (a public health-focused R&D fund based in New York), the Series B syndicate includes Seoul-based Korea Investment Partners, a leading technology investor in Asia and two Belgian technology investors: The Innovation Fund, supporting innovative chemistry and life sciences companies, and Inventures II, a leading impact venture capital fund. Rodolphe de Spoelberch, a Belgium-based independent private equity investor with a long-term horizon, is welcomed as an incoming Univercells board observer, while a variety of prominent private investors were federated by TheClubDeal, a private investment holding.
The Series B financing was catalyzed by new validations of the breakthrough biologics manufacturing solutions being pioneered at Univercells. The company’s flagship Sabin inactivated polio vaccine (sIPV) program recently achieved a 40-fold increase in polio D-antigen productivity compared to the benchmark process, and manufacturing cost estimates are within striking distance of the original goal of $0.15 per dose. With continued process development and high-efficiency fill-finish operations, the Univercells sIPV technology could enable a 10-fold reduction of the current public-sector sales price.
On the heels of these milestones, Univercells is concluding technology transfer negotiations with a number of established biologics manufacturers and healthcare providers in China, India and Latin America. In parallel, Univercells will be demonstrating the versatility of its technology platform by developing turn-key manufacturing solutions for two additional public health vaccines. With the current financing in place, Univercells has the resources to commercialize a diversified portfolio of technology solutions for a variety of vaccines, monoclonal antibodies and enzyme replacement therapies, with the first products available for human use as soon as 2019.
“The Univercells platform represents a unique win-win opportunity,” said Glenn Rockman, Partner at GHIF and incoming Univercells board member. “Its technology has incredible potential to make complex biologics more affordable and more widely accessible, while simultaneously pursuing an enormous commercial market opportunity.”
Hugues Bultot, CEO of Univercells, added: “We are delighted by all the encouragement and interest shown to us during this capital increase, which exceeded our expectations. I am convinced we have strategically expanded the circle of Univercells shareholders to include organizations and individuals with the potential to be long-term, value-added supporters of our rapidly growing company. Importantly, all of our investors are also very closely aligned with our mission to make biologics affordable to all;, they recognize the compelling financial return opportunities associated with that objective.”